跳至主要内容
临床试验/NCT05349669
NCT05349669已完成2 期

Cytokine With Jafron Haemoadsorption During Cardiopulmonary Bypass: Protocol for Randomized Controlled Report

Anthea Hospital Bari1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年5月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
cytokines levels

研究概览

简要总结

Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of Jafron to decrease peri-operative cytokine levels in cardiac surgery.

详细描述

In this context the investigators introduce the study design for multi-centre pilot randomized report in 40 patients undergoing elective CPB procedures with an expected time >120 minutes for each extracorporeal procedure. Patients will be randomly allocated to either standard of care (n = 20) or Jafron HA(n = 20) during cardiopulmonary bypass (CPB). The primary outcome will be the difference between the two groups in cytokines levels (IL-2, IL-6,TNF-α, IFN gamma) and secondary parameters (Fibrinogen, Albumin, Platelets, Hemoglobin, Hematocrit, White Blood Cells, Neutrophils,Lymphocytes, Monocytes, Eosinophils, Basophils) will measured at anaesthesia induction, at the endof CPB , Primary outcomes: hemodynamics with or without vasoconstrictors use, the mechanical ventilation (MV) (hours) time and length of stay in intensive care unit (ICU) (hours). This prospectivemulti-centre randomized controlled report will take place in two Centres: Anthea Hospital, GVMCare & Research, Bari, Italy; Virgen de la Arrixaca University Hospital, Murcia, Spain; between May 2022 and September 2022. The target population per centre will include (n=20) patients; will beallocate for each center to either standard of care (n = 10) or Jafron HA (n = 10) planned for elective cardiac surgery with increased risk of cytokine release.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
10 Years 至 100 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

CPB with Jafron

Experimental

Elective cardiopulmonary bypass (CPB) procedures with Jafron use with an expected time >120 minutes for each extracorporealprocedure.

干预措施: Jafron use during CPB (Drug)

结局指标

主要结局

cytokines levels

时间窗: 10 minutes after stop the cardiopulmonary bypass

IL-2, IL-6,TNF-α, IFN gamma,

Hemodynamics supports

时间窗: 10 minutes after stop of the cardiopulmonary bypass

vasoconstrictors use or not use

Post-operative ITEMS in intensive care unit

时间窗: 3 days after surgery

mechanical ventilation (MV) (hours) time and length of stay in intensive care unit (ICU) (hours)

次要结局

  • Markers levels(1 day before start of the cardiopulmonary bypass)
  • Markers(1 day after stop the cardiopulmonary bypass)
  • Hemodynamics supports(1 hour after stop the cardiopulmonary bypass)

研究者

发起方
Anthea Hospital Bari
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ignazio Condello

Principal Investigator

Anthea Hospital Bari

研究点 (1)

Loading locations...

相似试验